TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05554757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional rubber dam system
Description: rubber dam is a protective sheet with a hole that a dental professional positions over a tooth during an endodontic procedureEndodontists . This allows to isolate the treatment area with a dental clamp around the tooth. The dental sheet is placed around the in the Dental Rubber Dams and then a u-shaped device is hooked around. This isolates the single tooth where dental treatment will be conducted.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPTRADAM
Description: OptraDam Plus is a three-dimensional rubber dam that is flexible and has an anatomical shape, automatically stretched in an oral direction, an automatic hold of the device in the oral cavity is ensured.
Study: NCT05931250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC-Stimulator Plus (NeuroConn GmbH, Germany)
Description: Transcranial alternating current stimulation
Study: NCT05794503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, neostigmine.
Study: NCT05931250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sooma direct current stimulator (Sooma, Finland)
Description: Transcranial direct current stimulation
Study: NCT05643040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: femoral nerve block
Description: To evaluate the intraoperative analgesia effectiveness of femoral block in patients who will have knee surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adductor canal block
Description: To evaluate the intraoperative analgesia effectiveness of adductor canal block in patients who will have knee surgery.
Study: NCT05794503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, sugammadex
Study: NCT05786664

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of records

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete quality-of-life questionnaires

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study: NCT04198857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Develop a mobile app that supports self- management and treatment for Nepalese GDM patients
Description: We will use a user-centered design approach to develop a mobile app for GDM (GDM-DH) that matches the needs and technological sophistication of the target users. The goal of the app would be to assist patients in self management of GDM by improving their adherence to the recommended diet and physical activity regimens. The app will be used to collect information such as the carbohydrate consumption, the daily activity status and blood glucose and blood pressure measurements taken at home by the patients. The app will be set up in the phone of the participants and their data will be collected. The participants will be able to assess the usability and feasibility of the app. The app will also help clinicians by generating easily digestible visual displays of patient data and behaviors, which can aid in their clinical decision-making and counseling.
Study: NCT05206071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19+22 CAR-T cells
Description: Biological: CD19+22 CAR-T; Drug: Cyclophosphamide,Fludarabine;
Study: NCT06229665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valeda Light Delivery System
Description: The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
Study: NCT05990699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention program
Description: This program consists of eight sessions spanning across four weeks, each focusing on specific techniques and skills to aid in substance use disorder treatment. The first session emphasizes the correlation between the unconscious pilot and substance use, incorporating a corporeal examination technique to promote intentional concentration. The second session focuses on mindfulness to identify stimuli and observe accompanying sentiments, thoughts, and feelings. The third session introduces the ABSTEMIOUS space technique, urging patients to pause, observe their experiences, concentrate on breathing, broaden cognizance, and choose judicious responses in trying or hazardous situations. The remaining sessions address coping mechanisms for relapse risks, taking pragmatic action in high-risk situations, integrating healthy activities into life, and sustaining mindfulness practice through the development of a support network.
Study: NCT05528367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-PTX,S-1,Tirelizumab
Description: S-1:BSA \<=1.25 m2 ,80 mg daily; 1.25 m2 \<BSA \<1.5 m2,100 mg daily; BSA\>=1.5 m2 ,120 mg daily.~Nab-PTX:130mg/m2,d1，8，q3w；100mg qw(during radiation) Tirelizumab：200mg d1 q3w.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: 45-50Gy/25F
Study: NCT05675267

Intervention type: OTHER
Intervention: data collection
Description: HEART score calculation
Study: NCT04993729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T89 capsule
Description: T89 capsule (trade name Dantonic®) is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~T89 capsules, p.o. TID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T89 capsule
Description: T89 capsule (trade name Dantonic®) is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~T89 capsules, p.o. TID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsules, p.o. TID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsules, p.o. TID.
Study: NCT04962230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir
Description: PF-07321332/ritonavir administered orally as a single dose on Day 1, Period 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: In Period 2, Days 1-3, participants will receive low-dose of carbamazepine twice daily (BID), then a titrated mid-dose of carbamazepine BID on Days 4-7, and finally maintaining carbamazepine at the high-dose on Days 8-15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF 07321332/ritonavir
Description: In Period 2, Day 14, participants will receive a single dose of PF-07321332/ritonavir orally.
Study: NCT05643040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4in1 block
Description: To evaluate the intraoperative analgesia effectiveness of 4in1 block in patients who will have knee surgery.
Study: NCT05685082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized patient simulation
Description: The standardized patient simulation participants will receive a simulation with standardized patients on how to identify social determinants of health in an individual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manikin-based simulation
Description: The manikin-based simulation participants will receive a simulation with manikins on how to identify social determinants of health in an individual
Study: NCT04754724

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GIMate
Description: Use of GIMate to detect lactose malabsorption

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: GIMate
Description: Use of GIMate to detect lactose malabsorption

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: H2 Check
Description: Use of H2 Check to detect lactose malabsorption

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: H2 Check
Description: Use of H2 Check to detect lactose malabsorption
Study: NCT05483179

Intervention type: DIAGNOSTIC_TEST
Intervention: CPET
Description: Cardiopulmonary exercise test
Study: NCT04922983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: A position similar to the side-plank (Vasisthasana) held for maximal time at least once daily (usual duration: 30 - 90 seconds).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: A position similar to the side-plank (Vasisthasana) held for maximal time at least once daily (usual duration: 30 - 90 seconds).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Isometric Yoga-like exercise
Description: Extended torso and legs held diagonally by one straight arm, back against wall if necessary

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Isometric Yoga-like exercise
Description: Extended torso and legs held diagonally by one straight arm, back against wall if necessary
Study: NCT05700292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity Interval Training
Description: Training is based on 5 circuits, with intervals of 1 minute (high intensity) by 2 minutes (low intensity), with a total training time of 15 minutes (plus 5 more minutes of warm-up and 5 of cool-down exercises). The high intervals will be performed with the following exercises: squat, reverse lunge \& knee-up, reverse jump and walkout pushup, while the low intervals were performed jogging. The heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate of 85% to 95%. To monitor heart rate during training, a polar brand chest sensor, model H9, will be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity continuous training
Description: Continuous aerobic training (jogging). Also, the heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate from 60% to 75% and an increase in training time from 25 to 45 minutes (considering 5 minutes of warm-up and 5 of cool-down exercises). To monitor heart rate during training, a polar brand chest sensor, model H9, will be used as well.
Study: NCT04695002

Intervention type: BEHAVIORAL
Intervention: MIRA
Description: Based on the initial assessment, the citizen and professional agree what outcomes the citizen should report in MIRA. This could be pain, mood, sleep quality, energy level, dependent on the priorities of the citizen. Similarly, different activities are reported, e.g. exercise, social activities, prolonged sitting or work-related tasks. The citizen and the professional agree how often the citizen reports the outcomes and tasks, and the citizen is notified by the MIRA-app when it's time for reporting. The data will be visualized in a graph for the professional in the back-end of the system, making it possible for the citizen and the professional to view the same, real-time reported data. This provides the base for discussing and adjusting the course of rehabilitation as symptoms change over time. At the same time, this increases the citizen's knowledge of how symptoms, mood, sleep and activities all interact, thereby giving them the tools better cope with their health condition.

Intervention type: BEHAVIORAL
Intervention: Control
Description: Citizens in the control group participate in the standard course of vocational rehabilitation, without the use of MIRA app. Citizens are referred from the jobcenter if the case manager assesses that a health condition limits the citizen's ability to resume work. The typical course of rehabilitation lasts 4-12 weeks, and is managed by a physiotherapist, a psychologist and a physician. Depending on the condition of the citizen, the rehabilitation may be managed by only two of the three professionals. During the course of rehabilitation, the citizen may consult the team with varying frequency. If physical rehabilitation is part of the prescribed rehabilitation, the citizen shows up twice per week for several weeks of supervised exercise, whereas rehabilitation courses where self-management is in focus, only biweekly consultations may be provided. The decisions and planning of contents and duration of the rehabilitation programme is done in collaboration with the citizen.
Study: NCT05203978

Intervention type: PROCEDURE
Intervention: colonoscopy
Description: Colonoscopy

Intervention type: PROCEDURE
Intervention: colonoscopy
Description: Colonoscopy
Study: NCT05766904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Description: Four-component MenB vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Inj. B.P.
Study: NCT05694910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki has based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distance Reiki, Reiki practitioners followed the traditional Usui Reiki protocol healing.
Study: NCT05135858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucarpidase
Description: Glucarpidase (CPG2) Dose: 2000 U (2 vials of 1000 U per dose) 5 minutes-intravenous administration 24 hours after each Methotrexate infusion (i.e. 6 times in the whole protocol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: MTX will be administred 6 times during the protocol, at a variable interval of 8, 6 or 5 days. It will be administrated in a 2 to 3-hour IV infusion, at the dose of 3.5 g/m2 (body surface area capped at 2 m2). Each MTX administration will be preceded by a prehydration and will be followed by a posthydration
Study: NCT05203367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAR502
Description: Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 240 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 10, 50 and 150 mg. A maximum of 4 dose levels are pre-planned (10 mg, 50 mg, 150 mg, 300 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
Study: NCT04842474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gaze stability exercises and balance exercises
Description: Gaze stability exercises will be performed while patients are in a seated position. Each exercise will last for 30 seconds and be done in phases that included; eyeball movement, saccadic eye movement, pursuit eye movement, vergence eye movement, and vestibular-ocular reflex exercise. Balance exercises will be performed in a standing position including both static and dynamic training with or without closing eyes.
Study: NCT01004016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04922983

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Isometric Yoga-like exercise
Description: Extended torso and legs held diagonally by one straight arm, back against wall if necessary

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Used as placebo
Study: NCT06465264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allisartan Isoproxil/Amlodipine group 1
Description: One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine group 1
Description: One Amlodipine (5 mg) tablet and one placebo of Allisartan Isoproxil/Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allisartan Isoproxil/Amlodipine group 2
Description: One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Allisartan Isoproxil (240 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily.
Study: NCT06113432

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heart rate
Description: Heart rate calculation using electrocardiogram monitoring

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heart rate
Description: Heart rate calculation using electrocardiogram monitoring
Study: NCT04983992

Intervention type: PROCEDURE
Intervention: extracapsular release of lateral retinaculum
Description: A new kind of surgery releases the lateral retinaculum from outside the knee capsular, maintaining the structure of the knee capsular.
Study: NCT06199102

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol/ Devikap
Description: Infants in the monitored group will receive an initial dose of 1000 IU of vit D. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). At 28±2 days of age, blood samples will be obtained for 25(OH)D concentration measurement, followed by measurements every 4 weeks and/or 35±1 weeks of PCA. In the monitored group, vit D doses will be appropriately modified, based on 25(OH)D levels, using the scheme described in the Polish recommendation. The intake from the diet will be calculated from the second month of life.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol/ Devikap
Description: Infants in the controlled group will receive 250 IU for very low birth weight infants and 500 IU for infants weighing above 1000 g. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). Infants assigned to the standard therapy group will undergo the same blood sample collection procedure as the monitored group, but without any alterations in their dosing regimen.
Study: NCT06465264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allisartan Isoproxil group 2
Description: One Allisartan Isoproxil (240 mg) and one placebo of Allisartan Isoproxil/Amlodipine (240 mg/5 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily.
Study: NCT04946357

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Protons
Description: proton irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ions
Description: carbon ion irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
Study: NCT04784221

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation by protontherapy associated to nanoparticles injection
Description: Treatment for the study will be based on proton therapy and the administration of AGuIX® nanoparticles.~Protontherapy will be carried out for 4 consecutive weeks with 5 sessions per week (20 sessions) from D1 to D26.~The administration of the AGuIX® nanoparticle will be done on Days 1, 8 and 15 during protontherapy
Study: NCT05890807

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Front view photography of the patient's oral cavity with the help of a smartphone in the diabetology department.
Description: The diabetologist will take a photograph of the patient's oral cavity in the diabetology department.
Study: NCT05505227

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stigma-reduction training
Description: While the details will be finalized by the intervention working group after the key modifiable features of OUD-stigma among rural HCPs are isolated in Aim 1, our intervention will include several new elements that distinguish it from existing stigma-reduction interventions. The prototype intervention includes several modules aimed at decreasing stigma, increasing knowledge about medications for OUD, and increasing willingness to prescribe buprenorphine (see Table 3) among rural HCPs currently in practice.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HCPs affiliated with clinics in the control arm will receive no training but will be provided with a link to the SAMHSA website where prescribers can learn more about buprenorphine prescribing and apply to receive an X-waiver.
Study: NCT05906966

Intervention type: OTHER
Intervention: Phone contact
Description: . All mothers of children of born from cryopreserved oocytes will be contacted by phone and administered a questionnaire, to gather additional information about further psychomotor development of children.
Study: NCT05630859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NgG low dose investigational vaccine
Description: Two doses of NgG low dose investigational vaccine, administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NgG medium dose investigational vaccine
Description: Two doses of NgG medium dose investigational vaccine, administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NgG high dose investigational vaccine
Description: Two doses of NgG high dose investigational vaccine, administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses of placebo, administered intramuscularly.
Study: NCT05995223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Submaximal exercise protocol
Description: Participants will complete a submaximal walking protocol on a motorized treadmill, which consists of 4 times 6 minutes of walking at a moderate intensity speed and incline while their breathing, cardiac output, and muscle oxygen use is measured, with 10 minutes rest in between each bout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Submaximal exercise protocol
Description: Participants will complete a submaximal walking protocol on a motorized treadmill, which consists of 4 times 6 minutes of walking at a moderate intensity speed and incline while their breathing, cardiac output, and muscle oxygen use is measured, with 10 minutes rest in between each bout.